Table 2.
Multivariable analyses for factors associated with locoregional recurrence and disease-specific death
| Factor | HR | 95% CI | P value |
|---|---|---|---|
| Multivariable analysis for factors associated with locoregional recurrence | |||
| Age, y | |||
| ≤40 vs >40 | 1.669 | 1.167–2.385 | .005 |
| Race | |||
| Black/African American vs White | 1.601 | 1.032–2.483 | .036 |
| Hispanic/Latino vs White | 1.091 | 0.671–1.776 | .730 |
| Asian or American Indian/Alaska Native vs White | 2.329 | 1.353–4.009 | .002 |
| Overall pathologic stage | |||
| I vs 0 | 4.447 | 1.734–11.406 | .002 |
| II vs 0 | 5.026 | 1.974–12.799 | <.001 |
| III vs 0 | 6.833 | 2.547–18.332 | <.001 |
| Nuclear grade | |||
| III vs I-II | 1.225 | 0.840–1.788 | .290 |
| LVSI | |||
| Yes vs no | 1.657 | 1.110–2.474 | .014 |
| Type of definitive surgery | |||
| Mastectomy vs breast-conserving surgery | 0.360 | 0.219–0.593 | <.001 |
| Year of surgery | |||
| ≤2000 vs 2011–2017 | 1.347 | 0.849–2.137 | .210 |
| 2001–2010 vs 2011–2017 | 0.871 | 0.596–1.274 | .480 |
| Regional nodal irradiation | |||
| Yes vs no | 0.985 | 0.584–1.661 | .950 |
| Adjuvant hormone therapy | |||
| Yes vs no | 0.444 | 0.304–0.648 | <.001 |
| BRCA1/2 status | |||
| PV vs no mutation | 0.873 | 0.496–1.536 | .640 |
| Multivariable analysis for factors associated wtih disease-specific death | |||
| Age, y | |||
| ≤40 vs >40 | 1.532 | 1.179–1.991 | .001 |
| Race | |||
| Black/African American vs White | 1.679 | 1.195–2.360 | .003 |
| Hispanic/Latino vs White | 1.064 | 0.751–1.506 | .730 |
| Asian, American Indian/Alaska native vs White | 0.804 | 0.429–1.509 | .500 |
| Overall clinical stage | |||
| II vs I | 1.359 | 0.874–2.115 | .170 |
| III vs I | 1.707 | 1.056–2.758 | .029 |
| Overall pathologic stage | |||
| I vs 0 | 2.867 | 1.548–5.310 | .001 |
| II vs 0 | 3.363 | 1.894–5.972 | <.001 |
| III vs 0 | 5.317 | 2.950–9.582 | <.001 |
| Nuclear grade | |||
| III vs I-II | 1.697 | 1.246–2.310 | .001 |
| LVSI | |||
| Yes vs no | 1.234 | 0.926–1.645 | .150 |
| Type of definitive surgery | |||
| Mastectomy vs breast-conserving surgery | 1.555 | 1.130–2.141 | .007 |
| Year of surgery | |||
| ≤2000 vs 2011–2017 | 0.469 | 0.289–0.761 | .002 |
| 2001–2010 vs 2011–2017 | 0.780 | 0.586–1.039 | .090 |
| Nodes positive, no. | |||
| ≥10 vs <10 | 1.512 | 1.015–2.253 | .042 |
| Triple-negative and BRCA1/2 status | |||
| Non-TNBC: PV vs no mutation | 0.697 | 0.376–1.293 | .250 |
| TNBC: PV vs no mutation | 0.574 | 0.308–1.073 | .082 |
| PV: TNBC vs non-TNBC | 2.713 | 1.907–3.860 | <.001 |
| No mutation: TNBC vs non-TNBC | 2.236 | 0.973–5.136 | .058 |
Abbreviations: CI = confidence interval; HR = hazard ratio; LVSI = lymphovascular space invasion; PV = pathogenic variant; TNBC = triple-negative breast cancer.